Twitter | Search | |
Benoit Arsenault PhD
Associate Professor, Faculty of Medicine - Lipoproteins and Cardiometabolic Health Researcher at the Québec Heart & Lung Institute
7,180
Tweets
1,977
Following
5,138
Followers
Tweets
Benoit Arsenault PhD retweeted
Philippe Pibarot Dec 13
Congratulations to Paolo, et al. on this excellent paper supporting a link between PCSK9 and aortic vale disease. This provides support for a trial. PCSK9 Involvement in Aortic Valve Calcification
Reply Retweet Like
Benoit Arsenault PhD Dec 12
Replying to @ErinMichos
Thank you for sharing !
Reply Retweet Like
Benoit Arsenault PhD retweeted
Erin D. Michos, M.D. Dec 12
Interesting mouse model study by and colleagues. Might mean that therapy could be a novel pharmacological treatment for patients with calcific disease. This hypothesis needs to be confirmed in ongoing and future clinical trials.
Reply Retweet Like
Benoit Arsenault PhD retweeted
Pradeep Natarajan Dec 12
Reply Retweet Like
Benoit Arsenault PhD Dec 12
Thanks for sharing Pierre. Great to see our paper is finally published
Reply Retweet Like
Benoit Arsenault PhD retweeted
SABOURETCardiologist Dec 12
Reply Retweet Like
Benoit Arsenault PhD Dec 12
Replying to @CV_HealthNews
I will wait for the paper to be published, hopefully it will be released soon
Reply Retweet Like
Benoit Arsenault PhD retweeted
anahad oconnor Dec 11
Reply Retweet Like
Benoit Arsenault PhD Dec 12
Replying to @MBBoffa
Good point.
Reply Retweet Like
Benoit Arsenault PhD retweeted
Dr. James Underberg Dec 11
Great analysis by . We await the published results of ODYSSEY Outcomes Lp(a) analysis presented this June to further elucidate this complex and evolving story !
Reply Retweet Like
Benoit Arsenault PhD retweeted
Dave Dixon Dec 11
Great thread from on the (a) analysis from - Certainly promising but many questions remain...
Reply Retweet Like
Benoit Arsenault PhD retweeted
Raul Santos Dec 10
Quite interesting study ! Always elegant and Henry Ginsberg
Reply Retweet Like
Benoit Arsenault PhD retweeted
NYT Science Dec 11
The best diet for weight loss? "Eat the diet you like and stay with it.”
Reply Retweet Like
Benoit Arsenault PhD retweeted
Dr. Martha Gulati Dec 11
Our paper is out today! Gender differences in Patient reported outcomes: with ASCVD were more likely to report poorer patient experience, lower health‐related quality of life, and poorer perception of their health when compared with men
Reply Retweet Like
Benoit Arsenault PhD Dec 11
Replying to @ArsenaultBenoit
Achieving low apoB levels in patients with high Lp(a) is super important and I hope that the Lp(a) hypothesis will be tested specifically in pts with high Lp(a) using Lp(a)-specific therapies such as ASOs that lower Lp(a) levels by 80+% as LDL lowering is probably not enough
Reply Retweet Like
Benoit Arsenault PhD Dec 11
Replying to @ArsenaultBenoit
I think that what this paper shows is that PCSK9 inhibition works in patients with high Lp(a) levels because these patients are at high risk. The decrease in risk is likely due to the reduction in apoB containing particles, however.
Reply Retweet Like
Benoit Arsenault PhD Dec 11
Replying to @ArsenaultBenoit
Even more important is the differences in absolute (left) vs relative (right) changes in Lp(a). In patients who really need Lp(a) lowering (Q4), the relative change was 16%, an absolute reduction of 36 nmol/L. I doubt this change would translate into benefits but I could be wrong
Reply Retweet Like
Benoit Arsenault PhD Dec 11
Replying to @ArsenaultBenoit
The fact that changes in Lp(a) correlated with changes in the primary outcome (figure) might suggest an Lp(a) effect. This was however not observed for major coronary events. Changes in Lp(a) were also correlated with changes in LDL-C (and presumably apoB).
Reply Retweet Like
Benoit Arsenault PhD Dec 11
Replying to @ArsenaultBenoit
The million dollar question (IMO) is: Do these differences in benefits are observed simply because patients with high Lp(a) are at greater absoute risk or because of the Lp(a) lowering effects of PCSK9i? (evolocumab did reduce Lp(a) levels on average by 27%).
Reply Retweet Like
Benoit Arsenault PhD Dec 11
Replying to @ArsenaultBenoit
Interestingly, in this 25K+ high-risk patients trial, the benefits of PCSK9 inhibition with evolucumab appeared to be greater in patients with Lp(a) above the median, both in relative and absolute terms (p for interaction = 0.07).
Reply Retweet Like